Company Overview

Merck & Co., Inc. is a global, research-driven biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines, vaccines, biologic therapies, and animal health products. The company operates primarily in the pharmaceutical and animal health industries, with revenue driven by prescription medicines for oncology, vaccines, infectious diseases, cardiometabolic disorders, and immunology, as well as veterinary pharmaceuticals. Its key customers include hospitals, physicians, pharmacies, governments, and distributors serving both human and animal health markets.

Founded in 1891 as the U.S. subsidiary of the German Merck firm, Merck & Co. became an independent American company following World War I. Over time, it evolved into one of the world’s largest pharmaceutical companies through sustained internal research and targeted acquisitions. A defining strategic advantage has been its emphasis on large-scale clinical development, strong regulatory capabilities, and a diversified portfolio anchored by blockbuster therapies, particularly in oncology.

Business Operations

Merck operates through two primary business segments: Pharmaceutical and Animal Health. The Pharmaceutical segment generates the majority of revenue and includes oncology products (notably immuno-oncology therapies), vaccines, hospital acute care medicines, and treatments for chronic diseases. The Animal Health segment, conducted through Merck Animal Health, develops and markets veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals.

Operations are supported by a global manufacturing and research network, with significant investment in proprietary drug discovery platforms, biologics manufacturing, and vaccine technologies. Merck conducts extensive in-house research while also leveraging external collaborations, licensing agreements, and co-development partnerships. The company maintains numerous wholly owned subsidiaries and controlled entities to support regional commercialization, manufacturing, and R&D activities worldwide.

Strategic Position & Investments

Merck’s strategy centers on innovation-led growth, with a strong emphasis on expanding its oncology pipeline, advancing next-generation vaccines, and developing treatments for areas of high unmet medical need. The company consistently invests heavily in research and development, supported by one of the largest clinical trial programs in the pharmaceutical industry. Lifecycle management of existing products and expansion into new indications are core components of its growth strategy.

Strategic investments have included acquisitions and partnerships that strengthen Merck’s capabilities in biologics, immunotherapy, and digital-enabled health solutions. Notable acquisitions in recent years have expanded its late-stage pipeline and diversified revenue sources beyond its largest products. Merck is also actively involved in emerging areas such as novel vaccine platforms, biologic modalities, and precision medicine, while maintaining a disciplined capital allocation approach.

Geographic Footprint

Merck is headquartered in North America, with its global headquarters located in the United States. The company has a substantial international presence, operating in Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with products marketed in more than 140 countries. International markets represent a significant portion of total revenue, supported by regional manufacturing sites, research centers, and commercial operations.

The company’s global footprint enables it to participate in both mature and emerging healthcare markets, with particular strength in developed economies and growing exposure to faster-growing regions. Merck also engages in international public health initiatives and government partnerships, reinforcing its role in global vaccine distribution and infectious disease response.

Leadership & Governance

Merck is led by an experienced executive team with a strategic focus on science-driven innovation, operational discipline, and long-term value creation. The leadership philosophy emphasizes ethical governance, patient-centric development, and sustained investment in research while balancing shareholder returns.

Key executives include:

• Robert M. Davis – Chairman and Chief Executive Officer
• Caroline Litchfield – Executive Vice President and Chief Financial Officer
• Dr. Dean Y. Li – Executive Vice President and President, Research Laboratories
• Frank Clyburn – Executive Vice President and President, Human Health
• Rick DeLuca – President, Merck Animal Health